Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 20, Issue 15, 2002, Pages 3262-3269

  Witzig, Thomas E ^a   Flinn, Ian W ^a   Gordon, Leo I ^a   Emmanouilides, Christos ^a   Czuczman, Myron S ^a   Saleh, Mansoor N ^a   Cripe, Larry ^a   Wiseman, Gregory ^a   Olejnik, Teresa ^a   Multani, Pratik S ^a   White, Christine A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; INDIUM 111; RITUXIMAB; YTTRIUM 90;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG EFFICACY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 0036682214     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.017     Document Type: Article

References (33)

1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
2. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
3. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
4. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
5. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD 20 monoclonal antibody and CHOP chemotherapy
6. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
7. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
8. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
9. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
10. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma
11. Clinical experience with preparation of Zevalin (ibritumomab tiuxetan, IDEC-Y2B8/ IDEC-In2B8) using a radiolabeled kit
12. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma
13. Nonparametric estimation for incomplete observations
14. The functional assessment of cancer therapy scale: Development and validation of the general measure
15. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma
16. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
17. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients
18. Follicular lymphoma: Prognostic factors for response and survival
19. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma
20. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents
21. Second cancers following non-Hodgkin's lymphoma
22. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma
23. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma
24. Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies
25. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response
26. A clinical trial of anti-idiotype therapy for B cell malignancy
27. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
28. Response to Zevalin is superior to response to rituximab regardless of age and extent of disease
29. Reduced dose Zevalin is safe and effective in patients with relapsed or refractory, low grade, follicular or CD20+ transformed B cell non-Hodgkin's lymphoma (L/F/T NHL) and mild thrombocytopenia
30. 90Y Zevalin™ (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
31. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
32. Baseline peripheral blood B-cell levels correlate with disease-free interval and response to Zevalin radioimmunotherapy of relapsed non-Hodgkin's lymphoma
33. Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma